An observational study in Pancreatic Cancer, sponsored by National Cheng-Kung University Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 120 Years. Per ClinicalTrials.gov, last updated 2023-10-24.
Sponsored by National Cheng-Kung University Hospital · Observational
To assess the impact of preoperative sarcopenia and postoperative skeletal muscle wasting on the outcomes of patients with resectable pancreatic cancer who underwent pancreatectomy.
Previous studies have revealed that sarcopenia, defined as generalized loss of skeletal muscle mass, is a poor prognostic factor following surgery. However, research focusing on postoperative muscle wasting and its influence on the prognosis of resectable pancreatic cancer (PC) is limited. Investigators retrospectively reviewed 208 patients who underwent pancreatectomy for PC at the National Cheng Kung University Hospital (NCKUH) between June 2002 and April 2020. Clinical information regarding patient characteristics, pathological parameters, and biochemical features was collected from all patients using electronic medical records (EMRs) under an IRB-approved protocol (B-ER-110-420) at NCKUH. Preoperative psoas major area and the degree of muscle reduction at 3 months postoperatively were calculated using computed tomography to define sarcopenia and drastic muscle wasting. Patients were assigned to two groups based on sarcopenia or drastic muscle wasting, and compared for postoperative morbidity, disease free survival (DFS), and overall survival (OS).
3,311 studies on the registry are indexed under Pancreatic Neoplasms; 910 are open to participants now.
This study's enrollment of 208 is close to the median of 200 across 636 observational studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →National Cheng-Kung University Hospital is the lead sponsor of 276 studies on the registry; 71 are open to participants now.
Counted across the registry records on this site, refreshed daily.
20 Years and older (Adult, Older Adult ).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Overall survival
Overall survival was measured as the period between the date of resection and the date of the last follow-up or death.
Time frame: 10 years
Disease-free survival
Disease-free survival was defined as the duration from resection to cancer relapse (local, peritoneal recurrence, or distal metastasis).
Time frame: 10 years
Plan to share: No — The datasets generated and/or analyzed during the current study are not publicly available due to privacy issues.
No publications or documents are linked to this record.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cheng-Kung University Hospital →